Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial
曲妥珠单抗德鲁替康治疗既往接受过治疗的中国患者，其人表皮生长因子受体2阳性，局部晚期/转移性胃癌或胃食管交界处腺癌（DESTINY-Gastric06）：一项单臂、多中心、II期临床试验的结果
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103404
Peng, Zhi; Chen, Ping; Lu, Jin; Wan, Yiye; Zheng, Yulong; Ye, Feng; Yang, Jianwei; Liu, Ying; Pan, Hongming; Sun, Meili; Fan, Qingxia; Yuan, Ying; Chen, Kai; Sun, Zhuoer; Tian, Han; Xia, Ye; Shen, Lin
